- Report
- February 2026
- 250 Pages
Global
From €3998EUR$4,490USD£3,487GBP
- Report
- April 2026
- 30 Pages
Global
From €2449EUR$2,750USD£2,135GBP
- Report
- April 2026
- 30 Pages
Global
From €2449EUR$2,750USD£2,135GBP
- Report
- January 2026
- 196 Pages
Global
From €2226EUR$2,500USD£1,941GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2484EUR$2,789USD£2,166GBP
- Report
- November 2025
- 150 Pages
Global
From €4319EUR$4,850USD£3,766GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2226EUR$2,500USD£1,941GBP
- Report
- April 2025
- 200 Pages
Global
From €7080EUR$7,950USD£6,173GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1113EUR$1,250USD£971GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1113EUR$1,250USD£971GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1113EUR$1,250USD£971GBP
- Report
- August 2023
- 150 Pages
United States
From €3339EUR$3,750USD£2,912GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1336EUR$1,500USD£1,165GBP
P-Selectin is a type of hematological drug used to treat a variety of conditions related to the blood, such as thrombosis, inflammation, and cancer. It is a type of cell adhesion molecule that binds to other cells, allowing them to stick together and form clots. P-Selectin is also involved in the process of leukocyte rolling, which is important for the immune system to respond to infection.
P-Selectin is used in a variety of treatments, including anticoagulants, anti-inflammatory drugs, and cancer therapies. It is also used in research to study the role of cell adhesion molecules in the development of diseases.
The P-Selectin market is highly competitive, with many companies offering products for different applications. Some of the major players in the market include Merck, Pfizer, Novartis, Sanofi, and Bristol-Myers Squibb. Other companies include AstraZeneca, GlaxoSmithKline, and Roche. Show Less Read more
